Completed PHASE2 INTERVENTIONAL 8-arm NCT00460239

Buprenorphine's Dose Response Curve

Evaluation of Opioid Antagonist Activity in Humans

Sponsor: Johns Hopkins University

Interventions Buprenorphine Morphine Placebo

Updated 7 times since 2017 Last updated: Jan 11, 2017 Started: Jan 31, 2007 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Opioid-related Disorders and is currently completed. Johns Hopkins University leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States